EASL 2023

EASL 2023
June 21-24, 2023
Vienna, Austria

European Association for the Study of the Liver (EASL) Congress 2023.

Explore more information for Gilead Liver Diseases therapies
Results (9)

Evaluating utilization and management of comedications with potential for drug-drug interactions among patients with chronic hepatitis C initiating treatment with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

Long term safety profile of tenofovir alafenamide in chronic hepatitis B patients; final 8-year results of 2 phase 3 studies

Transcriptional analysis of HBV infected liver after treatment with selgantolimod reveals longitudinal changes in both inflammation-related pathways and B cell receptor repertoire

Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study

Long-term efficacy of tenofovir alafenamide in HBeAg-positive and -negative chronic hepatitis B patients treated for up to 8 years in 2 phase 3 studies

Concomitant use of Proton Pump Inhibitors and Sofosbuvir/Velpatasvir: Evidence from Randomized Clinical trials and Real-World Data

Results of a Phase 1b, open-label, multicenter study of selgantolimod (GS-9688) in special populations of patients with chronic hepatitis B abstract

Continued Treatment of Initial Non & Partial Virologic Responders with Bulevirtide Monotherapy Through Week 96 Leads to Improvement in Virologic & Biochemical Response

A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of cilofexor in non-cirrhotic subjects with primary sclerosing cholangitis (PRIMIS)